Under the coordination of KU Leuven, the consortium of partners from diverse disciplines, including clinical experts, medical practitioners, data scientists, and health economists, will be working on pioneering personalised therapies for brain cancer patients.
GLIOMATCH results contribute to new EIC-funded project GLIOBREAK
On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.
